Navigation Links
New Influenza Drug Inavir(R) TwinCaps(R) Launched in Japan
Date:10/21/2010

New Influenza Drug Inavir(R) TwinCaps(R) Launched in Japan -- LOURES, Portugal, October 21, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, New Products & Services Click to view news release full screen  

New Influenza Drug Inavir(R) TwinCaps(R) Launched in Japan

 

LOURES, Portugal, October 21, 2010 /PRNewswire/ -- Hovione has been advised by Daiichi Sankyo Company Ltd that Inavir(R) has been launched in Japan.

Inavir(R) is an inhalation powder which is delivered by the TwinCaps(R) inhaler to treat influenza. TwinCaps(R) was specifically designed by Hovione for this indication and is licensed to Daiichi Sankyo and to Biota Holdings Ltd.

Daiichi Sankyo has demonstrated that one 40mg dose of Inavir(R) active ingredient, laninamivir octanoate, is as effective as oseltamivir, a drug which needs to be taken over the course of 5 days. Daiichi Sankyo has announced it plans to supply the Japanese market with 4 million packs by end of March 2011, of which 2 million will be supplied by end of December 2010. The reimbursement price of the pack for adult treatment has been set at JPY 4161 (approx. EUR36; US$50).

TwinCaps(R) has been designed for extreme ease of use and very low cost. Daiichi Sankyo and Biota are responsible for licensing Ianinamivir.

About Hovione

Hovione is a leading developer of inhaled drug products, with experience in anti-virals and proteins delivered by inhalation, as well as inhaler development. It is an international company with 51 years' experience in Active Pharmaceutical Ingredient integrated development and compliant manufacture, from molecule to unit dose. In the inhalation area, Hovione is the only independent company offering such a broad range of services.

For more information about Hovione: please visit the Hovione site at http://www.hovione.com or contact Corporate Communications Isabel Pina +351-21-982-9362 e-mail: ipina@hovione.com
'/>"/>

SOURCE Hovione
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
2. Hoviones TwinCaps(R) Dry-powder Inhaler Approved in Japan as Part of Inavir(R) Influenza Treatment
3. FDA Accepts Sanofi Pasteur File Submission for Novel Influenza Vaccine Delivered by Intradermal Microinjection
4. Consumers Encouraged to Get Immunized Against Influenza
5. FDA Approves Vaccines for the 2010-2011 Influenza Season
6. NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines
7. IDRI and PATH Enter into Research Collaboration Agreement to Evaluate Novel Adjuvants to Enhance Pandemic Influenza Vaccines
8. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
9. Adamas Pharmaceuticals TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
10. AmpVacs a Broadly Protective Synthetic Influenza A Vaccine
11. NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, Inc. ... on providing the Urology, Uro/Gyn and Gynecology markets ... Ash Keswani has joined the Company as Senior ... newly created position, Mr. Keswani will report directly ... "Our organization is delighted that Ash ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ... their offering. ... for drug delivery technologies will rise from USD 20 Billion in ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... typically been previously exposed to more adverse experiences than children in the general ... trauma such as abuse, neglect or other family challenges. While no fault of ...
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to accept that hearing ... aid doesn’t have the stigma it had when great-grandpa wore his hearing aids years ... in a NALA North American Speaker Series (NASS) segment. “He probably wore ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... which name the Creator responds to and which He does not. Yisrayl says with ... which one is the true name, but he says with a little Scripture, backed with ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA is pleased to ... 20+ years of experience within the beauty industry, ranging from marketing, retail support, ... high-end cosmetic brands, retail brands and outlets in Canada and New York. As ...
Breaking Medicine News(10 mins):